ESTRO 2022 - Abstract Book

S32

Abstract book

ESTRO 2022

the conventional arm than in the short arm ( € 4,285 (95% CI: € 3,355– € 5,215) vs. € 3,062 (95% CI: € 2,368- € 3,756), p<0.05), as shown in Table 1. This was mainly due to transportation costs ( € 2,944 vs. € 1,754, p <0.01). QALY were significantly higher in the hypofractionated arm, with a difference of 0.037 (95% CI: 0.014 to 0.061).

Table 1. Total costs with incremental cost-effectiveness ratio per QALY in conventional and hypofractionated arms.

Conclusion Treating localized prostate cancer with moderate Hypofractionated RT is cost saving and improves slightly quality of life. Adopting such a treatment with an updated reimbursement rate would result in a lower global expense for the NHIS in France.

MO-0059 Cost and toxicity comparisons of two IMRT techniques for prostate cancer: a micro-costing study

I. Masson 1

1 Institut de Cancérologie de l'Ouest René Gauducheau , Radiotherapy, Saint Herblain, France

Purpose or Objective Intensity modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) has become the standard treatment for patients with high-risk prostate cancer. Two techniques of rotational IMRT are commonly used in this indication: Volumetric Modulated Arc Therapy (VMAT) and helical tomotherapy (HT). To the best of our knowledge, no study has compared their related costs and clinical effectiveness and/or toxicity in prostate cancer. We aimed to assess differences in costs and toxicity between VMAT and HT in patients with high-risk prostate cancer with pelvic irradiation. Materials and Methods We used data from the “RCMI pelvis” prospective multicenter study (NCT01325961) including 155 patients. We used a micro- costing methodology to identify cost differences between VMAT and HT. To assess the effects of the two techniques on total actual costs per patient and on toxicity we used stabilized inverse probability of treatment weighting. Results The mean total cost for HT, € 2019 3,069 (95% CI, 2,885 - 3,285) was significantly higher than the mean cost for VMAT € 2019 2,544 (95% CI, 2,443 – 2,651) (p <.0001). The mean ± SD labor and accelerator cost for HT was € 2880 (±583) and € 1978 (±475) for VMAT, with 81% and 76% for accelerator, respectively. Acute GI and GU toxicity were more frequent in VMAT than in HT (p=.021 and p=.042, respectively). Late toxicity no longer differed between the two groups up to 24 months after completion of treatment.